Dr. Othman received his Bachelor of Pharmaceutical Sciences from the Faculty of Pharmacy, Cairo University in 2001 and his PhD degree in Pharmaceutical Sciences from the University of Maryland Baltimore, USA in 2007. Dr. Othman's doctoral research was focused on novel therapies for treatment of cocaine abuse. After receiving his PhD, Dr. Othman’s research focused on characterization of the pharmacokinetics and pharmacodynamics of small molecules and novel biologics developed for treatment of several neurological and cognitive disorders (such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and cognitive impairment associated with schizophrenia) and more recently treatment of rheumatic and gastrointestinal autoimmune diseases. Overall, Dr. Othman has more than 13 years of clinical pharmacology and pharmacokinetic/pharmacodynamic modeling and simulations research experience in academic and pharmaceutical industry settings. Dr. Othman conducted research on more than 30 New Molecular Entities (NMEs) and 8 monoclonal antibodies at different stages of clinical development. Dr. Othman supported design, data analysis and/or interpretation of the results from more than 80 Phase I clinical trials, 30 Phase II clinical trials and 10 Phase III clinical trials. Dr. Othman supported successful filing of approximately 20 Investigational New Drug (IND) applications in the US, several Clinical Trial Applications (CTAs) in the EU and Japan and his research contributed to bringing new medicines to patients. Dr. Othman published 24 original research articles and co-authored 53 peer-reviewed abstracts for presentation at international scientific meetings. Dr. Othman is a member of the Rho Chi pharmacy honor society, a Fellow of the American College of Clinical Pharmacology and a co-chair of the AAPS Biomarkers in Translational Medicine focus group.